Ionis Pharmaceuticals posted better-than-expected revenue in the third quarter, but faced challenges as it prepares to bring ...

Cabanillas’ disclosures include grants from Genentech and Merck, personal fees from Novartis during the conduct of the study, ...

PD-1 and PD-L1 immune checkpoint inhibitors (ICIs) for treating advanced cancer were associated with an increased risk of new ...

Novartis AG's ( VTX:NOVN ) earnings announcement last week was disappointing for investors, despite the decent ...

With full confidence in China, where Novartis recorded 17 percent growth last year, one of the fastest among all major ...

In its latest financial report, Monte Rosa Therapeutics has announced a significant partnership with Novartis, alongside progress in its pipeline of drug candidates. The partnership involves a global ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...

With the seven-year experience of attending the China International Import Expo, Guan Hong, a senior executive at Novartis ...

At the time, the stock was trading at 26.08 euros a share. After successfully commercializing its star drug pelabresib, ...

In a recent order, Oberoi Realty Limited and Novartis India Limited have been instructed to provide a clear title of a 15,241 ...